A biotech company that hoped to use cell biology to address neurological disorders is shutting down.
Faze Medicines was built by VC Third Rock Ventures and launched in 2020 with $81 million from Third Rock, Casdin Capital, and venture funds run by drug giants Novartis, Eli Lilly, and AbbVie.
The company, which is based in Cambridge, Mass., planned to explore a new field called biomolecular condensates that was quickly garnering attention. Condensates are membrane-less clusters of molecules such as proteins and nucleic acids that help cells perform vital functions.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect